In vitro study demonstrates customizable, prolonged drug release from 3D-printed subcutaneous implants, highlighting their therapeutic potential for managing chronic conditions.
Implantable drug delivery devices offer many advantages over other routes of drug delivery. Most significantly, the delivery of lower doses of drug, thus, potentially reducing side-effects and improving patient compliance. Three dimensional (3D) printing is a flexible technique, which has been subject to increasing interest in the past few years, especially in the area of medical devices. The present work focussed on the use of 3D printing as a tool to manufacture implantable drug delivery devices to deliver a range of model compounds (methylene blue, ibuprofen sodium and ibuprofen acid) in two in vitro models. Five implant designs were produced, and the release rate varied, depending on the implant design and the drug properties. Additionally, a rate controlling membrane was produced, which further prolonged the release from the produced implants, signalling the potential use of these devices for chronic conditions.
No takes yet. Share an insight, caveat, or question.
Stewart et al. (2020) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: